MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces it will host a key opinion leader (KOL) call on Sudden Sensorineural Hearing Loss and SENS-401 as a potential treatment option on Thursday, July 23, 2020 at 12:30pm Eastern Time.
The call will feature a presentation by KOL Michael Hoffer, MD, FACS, University of Miami, who will discuss the disease characteristics and unmet medical need with regards to Sudden Sensorineural Hearing Loss (SSNHL). Dr. Hoffer will be available to answer questions at the conclusion of the call.
Sensorion's management team will also give an update on their pipeline candidate SENS-401, which is currently being evaluated in a Phase 2 Clinical Trial for treatment of SSNHL. SENS-401 is a 5-HT3 receptor antagonist and calcineurin inhibitor.
You can register for the webinar here.
Michael Hoffer, MD, FACS is a Professor of Otolaryngology and Neurological Surgery at the University of Miami. Dr. Hoffer assumed these roles after an over twenty-year military career in which he studied mild Traumatic Brain Injury (mTBI) and noise induced hearing loss on active duty service members. Dr. Hoffer is a clinician-scientist who performs both basic and clinical research along with his Otology/Neurotology clinical practice. Dr. Hoffer’s lab focuses on traumatic damage to the inner ear and brain. He is authored over sixty papers and several textbooks and has a particular expertise in noise induced hearing loss, dizziness and balance disorders as well as neurosensory consequences after mild traumatic brain injury (mTBI). Dr. Hoffer graduated from UCSD Medical School, was a resident at the University of Pennsylvania, and did a Neurotology Fellowship at the Ear Research Foundation. He has an active clinical practice in Otology/Neurotology and is very active in the University of Miami’s cochlear implant and hearing restoration services.
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. In the second half of 2019, Sensorion launched two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. The Company is uniquely placed, through its platforms and pipeline of potential therapeutics, to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders, a significant global unmet medical need.
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the ‘Document de référence’ registration document filed with the ‘Autorité des Marchés Financiers’ (AMF French Financial Market Authority) on September 7th, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.